IZB - Innovation and Start-up Center Biotechnology

How Can Indian and Bavarian Biotech Collaborations Thrive? 🇮🇳 Today, we had the privilege of welcoming the Indian Consul General in Munich, Shatrughna Sinha to the IZB - Innovation and Start-up Center Biotechnology in Martinsried. Prof. Ralf Huss from BioM Biotech Cluster Development GmbH and our Managing Director, Christian Gnam, shared insights about their organizations, showcasing the vibrant ecosystem on the Martinsried/Großhardern campus. 🌟 Our guests were impressed by the potential for innovation all in one place. The dynamic discussion that followed covered a number of key issues: 🌍 Opportunities for Collaboration: How can relationships between Indian and Bavarian biotech companies be forged? 💡 Harnessing Technology: What role does data and modern technology play in accelerating drug development? 📈 Identifying Promising Ventures: What makes a biotech company attractive to investors and partners? By the end of our meeting, it was clear that all participants wanted to continue the dialogue to improve international relations for our mutual benefit. #Biotech #InternationalCollaboration #campusmartinsried

"Biotech companies are the most risk-seeking, the extreme sports athletes among startups," says Christian Gnam, Managing Director of the IZB - Innovation and Start-up Center Biotechnology.🚀 In the latest episode of "Biotech Talk aus Bayern" by BioM Biotech Cluster Development GmbH, Christian shares his motivation for taking on the role of Managing Director, what excites him most about the biotech industry, and his vision for the future of the IZB and Martinsried as a hub for innovation. 📈 💡 🎙️ Want to gain insight? Tune in here: Spotify: https://lnkd.in/gv_d4Ymd Apple: https://lnkd.in/gn2vGZmP BioM Website: https://lnkd.in/dwEdnTrz #IZB #BioM #campusmartinsried #biotech

🌟 We are delighted to welcome ions.bio to our IZB - Innovation and Start-up Center Biotechnology Community! 🌟 At ions.bio, the passion for revolutionizing healthcare shines through their innovative approach. The start-up develops technologies to discover cutting-edge biomarkers that address pressing medical challenges. As experts in blood sample analysis, high-throughput omics screenings, and software development, they focus on improving early disease detection and creating new therapeutic approaches for conditions with limited treatment options.   🧬💡 To celebrate their move to the IZB campus, ions.bio hosted a party, inviting members from the Martinsried/Großhadern campus. This event perfectly embodies their commitment to fostering a strong community spirit from the very beginning. 🎈🎉 We’re excited to watch ions.bio embark on their journey to transform healthcare and welcome Dr. Sophia Viellechner (née Doll), Dr. Philipp E. Geyer, Dr. Sebastian Virreira Winter and Professor Jonathan Schmid-Burgk and the entire team to the IZB 🚀🌍 Want to know more about what drives Ions.bio? https://lnkd.in/dsVavc8e #IZB #campusmartinsried #Biotechnology #lifescience

🧬Exciting Clinical Milestone for SciRhom GmbH💊 IZB - Innovation and Start-up Center Biotechnology based Startup SciRhom GmbH has announced the first dosing of participants in their first-in-human clinical study for SR-878, their lead development program focused on first-in-class iRhom2 antibodies. This Phase 1 trial, in collaboration with the Medical University of Vienna, will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SR-878 in up to 48 healthy volunteers. The study is expected to read out in H2 2025. Dr. Juergen Reess, CMO of SciRhom, stated, “This milestone marks a transformational moment for the company. We aim to support the favorable safety profile of SR-878 observed in preclinical studies and advance swiftly to Phase 2 trials.” Dr. Jan Poth, Managing Director & CEO, added, “This event brings us closer to demonstrating the breakthrough potential of targeting iRhom2 to modulate disease pathways controlled by TACE/ADAM17.” With SR-878, SciRhom aims to provide innovative treatments for autoimmune diseases by blocking multiple pro-inflammatory pathways. We applaud the SciRhom Team for this remarkable achievement and eagerly anticipate what the future holds!🚀 Read more: https://lnkd.in/d9UByA7h #ClinicalTrials #AutoimmuneDiseases #Biotech #campusmartinsried #IZB Image Source: iStock/monkeybusinessimages

🚀 All for research excellence: leveraging the potential of the campus in cooperation with the Biomedical Center Munich The Martinsried/Großhadern campus, home to two Max Planck Institutes and LMU faculties as well as the IZB - Innovation and Start-up Center Biotechnology is not only a hub of concentrated knowledge but also a treasure trove of cutting-edge equipment and technologies that are invaluable to researchers. 🌟 In order to fully harness this vast potential of expertise and resources, the IZB seeks to play an active role. As part of our monthly Happy Hour, where all employees of our IZB-based start-ups are welcome, we invited special guests from the neighboring Biomedical Center Munich in October: Prof. Dr. Axel Imhof, Dr. Henrike Klinker and Prof. Dr. Steffen Dietzel. They introduced the participants to the Core Facilities at the BMC. These service and competence centers offer scientists access to state-of-the-art technologies in Bioinformatics, Protein Analysis, Bioimaging, Flow Cytometry and Biophysics.💡 Especially interesting: These resources are available not only to BMC scientists but also to external researchers! 🔬👩🔬👨🔬 In a lively discussion, the employees at IZB explored how they could harness these exciting opportunities for future collaborations and had the chance to pose their questions directly to the experts. We look forward to the new collaborations that will emerge from this! 💬🤝 Want to know more about the Core Facilities? Read here: https://lnkd.in/dD4GBkMT #Collaboration #Biotechnology #campusmartinsried #BMC #IZB

🌟 Welcoming the Serbian Delegation at the IZB in Martinsried 🌟 At the IZB - Innovation and Start-up Center Biotechnology in Martinsried, we had the pleasure of hosting the Serbian delegation led by Dr. Jelena Begovic, Minister of Science, Technological Development, and Innovation of the Republic of Serbia. The visit focused on exchanging knowledge and fostering collaboration, especially as biotechnology 🧬 plays a vital role in Serbia. Our CEO, Christian Gnam, introduced the IZB and its organizational structure 🏢, while Christoph Eckert, Project Manager at BioM, highlighted the comprehensive support that BioM Biotech Cluster Development GmbH provides to biotech start-ups through various initiatives 🚀. 🔬 Innovation promotion is also a priority in Serbia, which has made significant investments in developing a strong innovation ecosystem and infrastructure. A prime example is the BIO4 Campus 🏗️, currently under construction in Belgrade. Nenad Paunovic, EMBA presented the vision for this interdisciplinary research and development complex focused on four key areas: biomedicine 💊, biotechnology 🧪, bioinformatics 💻, and biodiversity 🌿. The BIO4 Campus will host a diverse community of tenants, creating an ideal ecosystem for innovation in life sciences 🔝. It was an enriching meeting for both sides, full of exciting ideas 💡 and shared experiences 🌍. A special thanks 🙏 to everyone involved for the inspiring discussions: • Dr. Jelena Begovic, Minister of Science Technological development and Innovation of the Republic of Serbia • Vladimir Radovanovic, Assistant Minister for Innovation, Technology Transfer and Technological Development • Nenad Paunovic, EMBA, EMBA, BIO4 Campus • Teodora Ilic, BIO4 Campus • Kosta Simonovic, Konsul ✨ Looking forward to future collaborations! ✨ #Biotechnology #LifeSciences #Serbia 🇷🇸 #BIO4Campus #IZB

🌍 Global Village of Biotechnology Meets International Science Leadership Today, we had the great honor of welcoming Patricia Gruber, Science and Technology Adviser to the U.S. Secretary of State, along with Linda Johnson and Kristina Mader to the IZB - Innovation and Start-up Center Biotechnology ain Martinsried. The visit once again highlighted that science and innovation know no borders. 🌐 The transatlantic exchange between the IZB and the U.S. is thriving, demonstrating the close collaboration in the fields of biotechnology and science. The U.S. and IZB are strongly connected: American companies have established themselves here, while IZB-based startups are expanding into the U.S. and opening branches. 🔄 Our Managing Director, Christian Gnam, introduced the IZB as a global innovation hub, and Christoph Eckert presented the work of the BioM Biotech Cluster Development GmbH and its international connections to biotech clusters in the U.S., Europe, and Asia. 🧬 A lively discussion followed on topics such as funding opportunities and the need to support universities and spin-offs. 💡 An inspiring day that reinforced the importance of international collaboration for the advancement of science and technology. 🚀 #Biotechnology #Innovation #GlobalVillage #USA #Germany #Science #Collaboration #IZB

Am I Attractive for Investment? - A critical question for emerging startups🚀   In today´s version of the IZBrunch, which we organized together with BioM Biotech Cluster Development GmbH , we brought in expert insights from across the Atlantic.🌎💼 This edition focused on answering: How can startups win over U.S. investors?   Featured Speakers: 🎤 Dean Farmer – A leading patent strategist in life sciences, Dean helps biotech and pharma companies safeguard their innovations. 🎤 Charles Cameron – Founder of Hub Angel Investment Fund, Charlie brings 17 years of global venture capital expertise across the U.S., Europe, and 40+ countries.   These U.S.-based experts shared invaluable insights on attracting international investors and the crucial factors to consider when bringing them on board.   Some Key Takeaways are: 🔑 Tighten your IP strategy 🔑 Identify product, market opportunity, milestones, and capital budgets 🔑 Build trust: Network face-to-face, communicate with VCs, and demonstrate real results. 🔑 Be prepared for longer timelines 🔑 Have plans for creative cost-cutting   Following their engaging presentations, we hosted a dynamic panel discussion featuring two leaders who have successfully secured U.S. funding for their companies: 🎤 Anne Burger – CFO of IZB - Innovation and Start-up Center Biotechnology based startup CatalYm GmbH, with over 15 years of biotech finance experience, including Rigontec’s impressive EUR 464M sale to MSD. 🎤 Dominik Schumacher – CEO of IZB - Innovation and Start-up Center Biotechnology based startup Tubulis GmbH, an award-winning entrepreneur and recognized as an MIT Innovator Under 35.   Thank you to our hosts: 🔸 Christian Gnam, Managing Director at IZB 🔸 Dr. Christoph Eckert, Project Manager at BioM Biotech Cluster Development GmbH   The insights from this edition of the IZBrunch have illuminated how emerging startups can attract U.S. investments. Our expert speakers and panelists demonstrated that with the right strategies, securing U.S. funding is achievable and can lead to substantial growth. 💡   Thank you to our speakers, panelists, hosts and the lively audience for your valuable contributions. We look forward to more engaging discussions in our future events! #IZB #biotech #USinvestment #biotechinvestment

🚀 United for Bavaria's Biotech Future: The Round Table Numerous institutions are investing not only their expertise but also a great deal of passion ❤️ to advance biotechnology in Bavaria. At the "Round Table of the Bavarian Biotechnology Cluster & Partners", organized by BioM Biotech Cluster Development GmbH, over 20 participants gathered at the IZB - Innovation and Start-up Center Biotechnology on September 26 – including representatives from BioPark Regensburg GmbH, Innovations- und Gründerzentrum (IGZ) Würzburg, Invest in Bavaria - The Business Promotion Agency of the State of Bavaria, Bayern Kapital, Bayerisches Staatsministerium für Wirtschaft, Landesentwicklung und Energie, and Bayerisches Staatsministerium der Finanzen und für Heimat – to name just a few. 🌐 Topics such as patents, the challenge of early-stage financing, and the need for more government support were discussed among many others. 💬 This led to the creation of important connections between the actors and their projects – fostering collaboration and networking! 🤝 A great example: BioM and the Bavarian AI Agency presented their joint cross-cluster project, "AI in Biotechnology." 🤖🔬 The objectives: To identify technical and thematic interfaces in the application of AI within biotechnology and provide companies with practical advice for implementation. 🎉 A big thank you to Ralf Huss, Birgitta von Glass, and the entire BioM Biotech Cluster Development GmbH team for organizing this fantastic event and enabling such valuable discussions! #Biotechnology #Innovation #AI #Bavaria #BioM #IZB

🧬Incredible Clinical Milestone for Eisbach Bio GmbH💊 The IZB - Innovation and Start-up Center Biotechnology based Startup Eisbach Bio GmbH has announced the dosing of the first patient in Module 1 of their Phase 1/2 MATCH clinical trial for EIS-12656, a groundbreaking first-in-class allosteric inhibitor targeting ALC1 in refractory advanced solid tumors. This trial, conducted at The University of Texas MD Anderson Cancer Center and co-funded by the Cancer Focus Fund, will assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of EIS-12656. Their small molecule inhibitor, EIS-12656, is designed to selectively target and inhibit the ALC1 chromatin helicase, a crucial player in DNA damage and repair. Adrian Schomburg, Ph.D., Founder and CEO of Eisbach, commented, “This milestone marks our entry into the cancer clinic with a transformative target and unique allosteric approach. EIS-12656 aims to address genetic and molecular vulnerabilities in tumors, potentially advancing as a drug that is both effective and well-tolerated.” We congratulate Adrian Schomburg and the Eisbach Team on this commendable achievement and are excited to see what the future holds!🚀 Read more: https://lnkd.in/dCuAr5ce #CancerResearch #ClinicalTrials #IZB #campusmartinsried Image Source: SeventyFour/istock